News & Updates

Sequential oral meds fall short, insulin remains best for gestational diabetes

14 Jan 2025 by

In the management of gestational diabetes, a sequential oral glucose-lowering medication strategy of metformin and additional glyburide, if needed, failed to demonstrate noninferiority to insulin, according to a study.

Sequential oral meds fall short, insulin remains best for gestational diabetes

14 Jan 2025

Ozanimod delivers real-world clinical benefits in ulcerative colitis

14 Jan 2025 by

Treatment with ozanimod (oza) attains high efficacy rates in real-world clinical practice at week 12 for advanced therapy (AT)-naive patients with moderate-to-severe ulcerative colitis (UC) and at week 26 for those with AT exposure, as shown by initial results from POLARIS, an ongoing phase IV open-label study.

Ozanimod delivers real-world clinical benefits in ulcerative colitis

14 Jan 2025

Testosterone does not induce recurrence in men after RP

14 Jan 2025

Select men who underwent radical prostatectomy (RP) for organ-confined prostate cancer may safely use testosterone therapy, which does not seem to cause biochemical recurrence (BCR), according to a study.

Testosterone does not induce recurrence in men after RP

14 Jan 2025

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

14 Jan 2025 by

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

14 Jan 2025

Alectinib trumps crizotinib for ALK+ NSCLC

13 Jan 2025 by

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Alectinib trumps crizotinib for ALK+ NSCLC

13 Jan 2025

Metformin may reduce asthma attacks

12 Jan 2025

The glucose-lowering drug metformin appears to be associated with fewer asthma attacks, with further reductions when metformin is used in combination with GLP-1RAs, according to a study.

Metformin may reduce asthma attacks

12 Jan 2025

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

11 Jan 2025

Patients with inflammatory bowel disease (IBD) who achieve a normal C-reactive protein (CRP) and endoscopic healing exhibit significantly higher ustekinumab trough levels, reveals a study. A cutoff level of 4.8 µg/mL predicts CRP normalization.

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

11 Jan 2025

Anti-CGRP monoclonal antibodies pose no increased CVD risk

11 Jan 2025

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor do not appear to contribute to heightened risk of cardiovascular disease (CVD) relative to onabotulinumtoxinA in adults with migraine at high CVD risk, according to a study.

Anti-CGRP monoclonal antibodies pose no increased CVD risk

11 Jan 2025

Blinatumomab plus chemo improves survival in paediatric B-ALL

10 Jan 2025 by

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.

Blinatumomab plus chemo improves survival in paediatric B-ALL

10 Jan 2025

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

10 Jan 2025 by

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

10 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Sequential oral meds fall short, insulin remains best for gestational diabetes

Sequential oral meds fall short, insulin remains best for gestational diabetes

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Ozanimod delivers real-world clinical benefits in ulcerative colitis

Testosterone does not induce recurrence in men after RP

Testosterone does not induce recurrence in men after RP

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

Alectinib trumps crizotinib for ALK+ NSCLC

Alectinib trumps crizotinib for ALK+ NSCLC

Metformin may reduce asthma attacks

Metformin may reduce asthma attacks

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

Anti-CGRP monoclonal antibodies pose no increased CVD risk

Anti-CGRP monoclonal antibodies pose no increased CVD risk

Blinatumomab plus chemo improves survival in paediatric B-ALL

Blinatumomab plus chemo improves survival in paediatric B-ALL

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma